Effective Head and Neck Tumor Markers: The Continuing Quest

Me, Ropka; Wj, Goodwin; Pa, Levine; Ct, Sasaki; Jc, Kirchner; Rw, Cantrell

doi:10.1001/archotol.1991.01870210083016

Cited by 19 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Single TM sensitivity was not shown to be greater than 50% and in many instances less than that 11 . Although not a universal finding, 8 a higher sensitivity of up to 72% was reached 2,7 if some of the potential TMs were used in a parallel combination of two or more. Table II portrays basic data of some of the recent studies on head and neck TM.…”

Section: Discussionmentioning

confidence: 78%

“…SCCA levels were also studied in 85 patients by Clasen et al, 6 demonstrating 53% sensitivity. The clinical value of SCCA and LASA was also evaluated by Ropka et al 7 in a two‐center study. A relatively high sensitivity (63.4%) was found for LASA, while a 27.6% sensitivity was found for SCCA.…”

Section: Discussionmentioning

confidence: 99%

“…The quest for such a TM for cancer of the head and neck continues, but to date no marker has yet fulfilled these minimal requirements. Numerous studies 1‐14 have shown discouraging results as to the practical value of a variety of serum factors. These have included squamous cell carcinoma antigen (SCCA), 2,4‐10 lipid‐associated sialic acid (LASA), 2,3,8‐10 carcinoembryonic antigen (CEA), 8‐10 glycoproteins, 12 and immune complexes 13,14 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Elevated Arginine Vasopressin Levels in Squamous Cell Cancer of the Head and Neck

Talmi¹,

Wolf²,

Hoffman³

et al. 1996

The Laryngoscope

View full text Add to dashboard Cite

The reported effectiveness of single tumor markers (TMs) associated with squamous cell cancer of the head and neck ranges from 15% to 71%, with most studies reporting sensitivity no higher than 50%. An increased incidence of the syndrome of inappropriate secretion of antidiuretic hormone or arginine vasopressin (SIADH) in patients with head and neck cancer has been reported. Serum arginine vasopressin (AVP) was studied as a possible TM in these patients. Sixty-three patients with squamous cell carcinoma of the head and neck determined as potentially curable were prospectively evaluated before treatment and compared to 17 patients with apparent cure of head and neck squamous cell cancer who served as controls. Serum AVP levels were obtained and determined by radioimmunoassay in the preoperative period and 1 week postoperatively in 15 patients. Thirty-four patients were staged as T4, 26 as T3, and 3 as T2. Twenty-one (33%) of the 63 patients had no neck involvement. Twenty-four (38%) of 63 patients had elevated serum AVP levels corrected for serum osmolarity. Of the 15 patients evaluated before and after surgery, 8 (53%) had elevated serum AVP levels preoperatively. Of these 8 patients, 3 had reduction in AVP levels and 5 had complete normalization after 1 week. The result obtained for serum AVP do not exceed results of other TMs reported. AVP may also not be as specific as other TMs for cancer of the head and neck. Our group with AVP sampled postoperatively is too small for us to draw conclusions, but reduction of its levels after treatment in all patients may be significant. These preliminary results indicate that further evaluation of AVP during the posttreatment course in a larger number of cases, and perhaps with other TMs as well, is warranted.

show abstract

Section: Discussionmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Elevated Arginine Vasopressin Levels in Squamous Cell Cancer of the Head and Neck

Talmi¹,

Wolf²,

Hoffman³

et al. 1996

The Laryngoscope

View full text Add to dashboard Cite

show abstract

“…Early studies reported very low sensitivity of various markers like CEA (carcinoembryonic antigen) (Silverman et al, 1976;Walther et al, 1990), Lipid associated sialic acid (Katopodis et al, 1982;Ropka et al, 1991) and SCC-marker (TA-4) (Calsen et al, 1990;Daver et al, 1990;Fichbach et al, 1990;Walther et al, 1990;Yoshimura et al, 1990;Ropka et al, 1991) in head and neck cancer patients. Cyfra 21-1 was reported as a new marker for non-small cell carcinoma of the lung (Pujol et al, 1993;Stieber et al, 1993;Rastel et al, 1994).…”

mentioning

confidence: 99%

The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease

et al. 2000

View full text Add to dashboard Cite

Summary This study examines a new tumour marker, Cyfra 21-1, as a prognostic marker in predicting the survival of H&N cancer patients, and its correlation with clinical outcome during prolonged follow up of these patients. The study included 67 patients with primary detection of carcinoma of H&N. The survival of these patients was evaluated in correlation with the disease stage and Cyfra 21-1 levels at initial diagnosis. 38 patients were followed clinically and with serial assays for at least 12 months, or until recurrence was diagnosed. Cyfra 21-1 levels were determined periodically, using an Elisa kit. Patients with Cyfra 21-1 < 1.5 ng ml -1 had a higher survival rate compared to patients with Cyfra 21-1 ≥ 1.5 ng ml -1 (63% vs. 20%, respectively). The risk ratio of Ln(Cyfra 21-1) is 1.62 (P = 0.028). In a Cox regression model that included the disease stage and Ln(Cyfra 21-1), Ln(Cyfra 21-1) was preferred as the main parameter for predicting patients survival. In 83% of the 12 patients with recurrent or residual disease, Cyfra 21-1 was elevated before or during clinical detection of the recurrence. Cyfra 21-1 was found to be a prognostic marker for carcinoma of H&N, unrelated to the stage of the disease. Elevated levels of Cyfra 21-1 without clinical evidence of disease can be attributed to the marker's mean lead-time as compared to the clinical appearance of the disease.

show abstract

“…Subsequently, commercial radioimmunoassay and enzyme immunoassay were developed to measure the level of SCC Ag in human serum or plasma. So far it has been measured in tumours of the cervix, head and neck, lungs, oesophagus, rectum and skin .4−29 The purpose of this study was to determine the usefulness of SCC Ag in patients with cancer of the larynx.…”

mentioning

confidence: 99%

Squamous cell carcinoma antigen in patients with cancer of the larynx

Lachowicz¹,

Hassmann-Poznanska²,

Kozłowski

et al. 1999

Clin Otolaryngol

View full text Add to dashboard Cite

The purpose of this study was to evaluate the clinical usefulness of squamous cell carcinoma antigen (SCC Ag) in patients with squamous cell carcinoma of the larynx. Plasma specimens were obtained from 70 patients with cancer of the larynx before and after treatment and during follow-up. Disease status and the marker levels were determined blind to each other. Microparticle enzyme immunoassay (IMx SCC) was used to measure the SCC Ag level. Applying standard normal limits the sensitivity of the marker at diagnosis was 25.7%. SCC Ag levels were generally lower after therapy than before. Relapse occurred more often in patients with an abnormal pretreatment SCC Ag level, which was more frequent in those with nodal invasion. The marker level increased in 70% of the patients with relapse before the clinical detection of recurrence. SCC Ag is of limited usefulness in the primary diagnosis of cancer of the larynx, but is useful in detecting recurrence of cancer.

show abstract

Effective Head and Neck Tumor Markers: The Continuing Quest

Cited by 19 publications

References 16 publications

Elevated Arginine Vasopressin Levels in Squamous Cell Cancer of the Head and Neck

Elevated Arginine Vasopressin Levels in Squamous Cell Cancer of the Head and Neck

The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease

Squamous cell carcinoma antigen in patients with cancer of the larynx

Contact Info

Product

Resources

About